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Abstract
CUL9 is a member of the cullin family of E3 ubiquitin ligases, and it localizes predominantly in 
the cytoplasm. Deletion of Cul9 in mice results in increased DNA damage, widespread 
aneuploidy, spontaneous tumor development, accelerated Eμ-Myc-induced lymphomagenesis, and 
susceptibility to carcinogenesis. CUL9 binds to p53 and causes cell apoptosis when ectopically 
expressed. Whether the function of CUL9 in maintaining genomic integrity and suppressing 
tumorigenesis is linked to p53 has not been genetically tested. Here, we report that deletion of 
CUL9 in human cells results in attenuated p21 induction and impaired cellular response to DNA 
damage. We show that disruption of Cul9-p53 binding in mouse embryo fibroblasts (MEFs) by a 
knock-in mutation in Cul9 (Δp53) increases S-phase cell population, accumulates DNA damage 
during DNA replication, and decreases apoptosis to both endogenous and exogenous DNA-
damaging agents. The extent of these alterations in Cul9Δp53 MEFs is indistinguishable to those 
seen in Cul9-/- MEFs and comparable to those seen in p53-/- MEFs. Deletion of CUL9 in p53 null 
cells does not lead to further increase of DNA damages. Both Cul9-/- and Cul9Δp53 MEFs 
proliferate faster and undergo spontaneous immortalization while retaining both Arf and p53. 
These results demonstrate that the functions of CUL9 in regulating cell proliferation and 
maintaining genomic integrity are mainly mediated by p53, and that CUL9 is a critical p53 
activator.
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The tumor suppressor p53 functions to maintain genomic integrity and to suppress 
tumorigenesis1. Deletion of p53 in mice results in spontaneous immortalization of mouse 
embryonic fibroblasts (MEFs) and tumorigenesis2. Mutations in the p53 gene are the most 
common genetic alterations in diverse types of human cancer3, and in tumors retaining 
wildtype p53, genes involved in its regulation are frequently mutated4. The regulation of p53 
is carried out primarily by protein modifying enzymes, and extensive biochemical and 
cellular studies have provided mechanisms on how these enzymes signal different stresses to 
p53. As each of these p53 regulatory enzymes has other non-p53 targets, one important area 
surrounding p53 regulation not adequately studied is the effect of disrupting the interaction 
between p53 and its regulators.
CUL9 belongs to the cullin family of proteins which functions as a scaffold to assemble E3 
ubiquitin ligases. CUL9 (2,517 aa) is the largest and evolutionarily youngest member of the 
cullin family, evolving after the emergence of vertebrates5, and it contains multiple 
functional domains. Two unique features of CUL9 are that it localizes predominantly in the 
cytoplasm and it binds to p536, 7. Deletion of Cul9 in mice results in abnormal nuclear 
morphology, increased DNA damage, and widespread aneuploidy in multiple tumors that 
develop spontaneously in multiple organ and tissues. In addition, Cul9-/- mice experience 
accelerated Eμ-Myc-induced lymphomagenesis and are rendered susceptible to 
carcinogenesis8, 9. Whether CUL9 plays a similarly important function in maintaining 
genomic integrity in human cells and how much of this function of CUL9 is dependent on 
p53 have not been determined.
Results
Loss of CUL9 function reduces basal and DNA damage-induced p21 in human cells
To determine the function of CUL9 in maintaining genomic integrity in human cells, we 
knocked down CUL9 in human U2OS osteosarcoma cells which retain wildtype p53 (Figure 
1a). Although the steady state level of p53 did not change significantly, the basal level of the 
CDK inhibitor p21, a target of p53, was consistently reduced by nearly 50%. Knocking 
down CUL9 also reduced p21 accumulation after a low dose etoposide treatment (2 μM) by 
more than 50% without significantly reducing the steady state level of p53 protein (Figure 
1b). To confirm these findings, we used the CRISPR-Cas9 system to delete the CUL9 gene 
in U2OS cells (Figure 1c and Supplementary Figure S1a, S1a and S1c). We found that 
deletion of CUL9 also resulted in reduced basal p21 level and p21 accumulation after 
etoposide treatment without changing the induction of the steady state level of p53 protein 
(Figure 1c) significantly. Together, these results demonstrate that the function of CUL9 is 
required for maintaining the basal and induced expression of p21 in response to DNA 
damage in human cells.
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Loss of function of CUL9 accumulates damaged DNA and alters the cell cycle in human 
cells
Endogenous DNA damage occurs spontaneously during cell proliferation, representing a 
major source of DNA damage10. To determine the effect of loss of function of CUL9 on 
endogenous DNA damage, we stained CUL9-depleted or deleted U2OS cells with an 
antibody recognizing γ-H2AX11. We found that deletion of CUL9 resulted in a significant 
increase (3.9-fold) of the number of γH2AX-positive cells (defined as ≥5 foci per cell), from 
9.7% in parental CUL9+ U2OS cells to 37.9% in CUL9-KO U2OS cells (Figure 1d). 
Moreover, the number of γH2AX foci in the γH2AX-positive cells was also significantly 
increased by CUL9 deletion (2.3-fold), from an average of 7.9 per cell in parental CUL9+ 
U2OS cells to 18.2 in CUL9-KO U2OS cells. The same result was obtained in U2OS cells 
after CUL9 knockdown which increased both γH2AX-positive cells, from 11.6% in control 
U2OS cells to 26.2% in CUL9-depleted U2OS cells (2.3-fold, Supplementary Figure S1d), 
and the number of γH2AX foci in the γH2AX-positive cells, from an average of 5.8 foci per 
cell in control cells to 12.5 in CUL9-depleted U2OS cells (2.2-fold).
Deletion of CUL9 in p53 null cells does not further increase of endogenous DNA damages
To determine the genetic interaction between CUL9 and p53 in suppressing endogenous 
DNA damage, we deleted p53 in both parental and CUL9-KO U2OS cells (referred to as 
p53-KO and p53-CUL9 DKO, respectively, Figure S1e) and determined the endogenous 
DNA damage in these cells by γ-H2AX staining. We found that deletion of p53 resulted in a 
significant increase of the number of γH2AX-positive cells (3.1-fold), from 11.9% in 
parental p53+ U2OS cells to 36.5% in p53-KO U2OS cells (Figure 1e). The number of 
γH2AX foci per individual γH2AX-positive cell was also significantly increased in p53-KO 
U2OS cells by 2.1-fold, from an average of 8.8 γH2AX foci per cell in parental p53+ U2OS 
cells to 18.1 foci in p53-KO U2OS cells. Notably, the increases in both γ-H2AX foci and 
number of γH2AX foci per cells caused by p53 deletion were similar to CUL9 deletion. 
Importantly, the percentage of γ-H2AX positive in p53-CUL9 DKO U2OS cells (35.7%) 
was similar to those detected in either p53-KO cells (36.5%) and slightly higher than those 
accumulated in CUL9-KO cells (31.5%) (Figure 1e). These results demonstrates that 
deletion of CUL9 in p53 null cells does not further increase DNA double strand breaks, 
supporting the notion that the function of CUL9 in preventing endogenous DNA damage is 
mediated primarily by p53.
Loss of function of CUL9 impairs cellular response to exogenous DNA damaging agent
Flow cytometry analysis showed that CUL9 depletion slightly increased the proportion of S-
phase cells as compared with control cells, from 16.4% to 17.7%, in the absence of 
exogenous DNA-damaging agent, but resulted in a significant (2.0- and 2.4-fold) increase of 
S-phase cells after 24 hours of treatment with either 2.5 μM or 5.0 μM etoposide, 
respectively (Figure 1f). Deletion of CUL9 resulted in a more pronounced increase (72%) of 
S-phase cells, from 9.4% to 16.2% in the absence of an exogenous DNA damage agent, and 
an even more significant (3.5-fold) increase of S-phase cells than CUL9-depleted U2OS 
cells after being exposed to 5 μM etoposide for 24 hours, from 12% to 42.5% (Figure 1g). 
The increase of S-phase cells after CUL9 depletion was accompanied by a reduction of the 
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G1 cell population. There was a clear decrease in the sub-G1 cell population in CUL9-KO 
cells when compared to control CUL9+ U2OS cells, from 4.9% to 1.8% (2.7-fold) in the 
absence of exogenous DNA damage and from 6.0% to 2.5% (2.4-fold) after etoposide 
treatment. Together, these results demonstrate that loss of CUL9 function, like loss of p53 
function, alters cell cycle control and impairs DNA damage response to both endogenous 
and exogenous DNA-damaging agents.
Disruption of Cul9-p53 binding impairs cellular response to DNA damage
We previously identified several single amino acid substitutions in the p53-binding region of 
human CUL9, including Q417A, that disrupts its binding with p5312. To determine whether 
the function of CUL9 in maintaining genomic integrity is linked to p53, we knocked in a 
mutation to the mouse Cul9 gene—Q418A (equivalent to human Q417A substitution)—in 
ES cells and derived both heterozygous and homozygous mutant MEFs (referred to as 
Cul9Δp53/+ and Cul9Δp53/Δp53, respectively). We verified that this mutation, like its human 
homologous Q417A mutation, almost disrupted Cul9-p53 binding completely, without any 
significant effect on the binding of Cul9 with Roc1 (Figure 2a). Like deletion of Cul9 in 
MEF (Supplementary Figure S2a), disruption of Cul9's binding with p53 resulted in 
decreased and delayed p53 phosphorylation on Ser15 and reduced accumulation of p53 and 
p21 protein (Figure 2b). These results indicate that Cul9 regulates p21 through p53 that 
Cul9. Accumulation of Ser15-phosphorylated p53 in Cul9Δp53/Δp53 MEFs following 
etoposide suggests that Cul9, although affecting p53 level in MEFs, does not play a direct 
role in regulation of Ser15 phosphorylation of p53. Disruption of Cul9's binding with p53 
had no detectable effect on the steady state level of survivin, a substrate of Cul9 E3 ligase8, 
suggesting that Cul9-p53 binding is not required for the regulation of survivin ubiquitylation 
by Cul9.
Disruption of p53 binding in Cul9 resulted in a significant increase (4.95-fold) of γH2AX-
positive cells, from 8.5% in wild-type MEFs to 42.1% in Cul9 Δp53/Δp53 MEFs (Figure 2c). 
Likewise, the number of γH2AX foci in the γH2AX-positive cells was significantly 
increased (1.9-fold) by the disruption of Cul9-p53 binding, from an average of 8.9 foci per 
positive cell in wild-type MEFs to 17.3 in Cul9 Δp53/Δp53 MEFs. Deletion of p53 also 
resulted in a significant increase of both the percentage of γH2AX-positive cells (by 5.35-
fold) and the number of γH2AX foci in the γ-H2AX-positive cells (by 2.22-fold), from 
9.4% γH2AX-positive cells and 8.5 γH2AX foci per γ-H2AX-positive cell in p53 wild-type 
MEFs to 50.3% and 18.9 in p53-/- MEFs, respectively (Figure 2d). Both increases of the 
percentage of γH2AX-positive cells and the number of γH2AX foci in each cell seen in 
Cul9 Δp53/Δp53 MEFs were comparable to those seen in p53-/- MEFs, suggesting that Cul9 
plays a major role in signaling p53 in the maintenance of genomic integrity. Supporting a 
major role of Cul9 in signaling to p53, the p21 level was reduced similarly in Cul9Δp53/Δp53 
MEFs as in p53-/- MEFs when compared to wildtype MEFs (Figure 2b and 2c).
To determine the genetic interaction between CUL9 and p53 in suppressing endogenous 
DNA damage in MEFs, we generated p53-Cul9 double knockout (DKO) MEFs 
(Supplementary Figure S2b) and determined endogenous DNA damage by γH2AX staining. 
We found that both the percentage of γ-H2AX positive cells and the number of γH2AX foci 
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per cells in p53-Cul9 DKO MEFs (44.7% and 19.9 γH2AX foci per cell) were similar to 
those detected in either p53 MEFs (43.5% and 21.1 foci per cell), but were somewhat higher 
than those detected in the Cul9 MEFs (39.2% and 18.6 foci per cell) (Figure 2e). These 
results support the notion that the function of CUL9 in preventing endogenous DNA damage 
is mediated most by p53 in MEFs, as is the case in U2OS cells.
Disruption of Cul9-p53 binding accumulates DNA damage during replication and reduces 
apoptosis
In human U2OS cells, depletion or deletion of CUL9 results in a significant increase of S-
phase cell population and a decrease in the sub-G1 cell population (Figure 1). To probe the 
link between the function of CUL9 in maintaining genomic integrity and in cell cycle 
checkpoint control, we determined when the spontaneous DNA damage occurred in the cell 
cycle and how this is affected by the disruption of Cul9-p53 binding. We pulse-labelled 
exponentially-growing cells for 30 minutes with 5-ethynyl-2′-deoxyuridine (EdU), a 
thymidine analogue, and identified cells undergoing active DNA synthesis using a 
fluorescent azide to detect incorporated EdU 13 and DNA damage using γH2AX antibody. 
EdU-positive cells were increased from 14.2% in wildtype MEFs to 26.7% in Cul9 Δp53/Δp53 
MEFs, 32.3% in Cul9-/- MEFs and 37.4% in p53-/- MEFs (Figure 3a), indicating a 
significant increase of the S-phase cell population by the deletion of p53 or Cul9, or the 
disruption of Cul9-p53 binding with loss of p53 being the most potent in stimulating DNA 
replication. The percentage of γH2AX-positive cells was increased from 13.9% in wildtype 
MEFs to 30.7% in Cul9 Δp53/Δp53 MEFs, 29.2% in Cul9-/- MEFs and 36.5% in p53-/- MEFs, 
indicating a significant increase of DNA damage by either the deletion of p53 or Cul9 or the 
disruption of Cul9-p53 binding. Compared to the wildtype MEFs which had 14.2% EdU- 
and 14.9% γH2AX-positive cells, Cul9 Δp53/Δp53 and Cul9-/- MEFs had similar increases in 
S-phase population (26.7% vs 29.2%) and γH2AX-positive cells (29.3% vs 32.3%), 
suggesting that the functions of Cul9 in preventing the accumulation of endogenous DNA 
damage and regulating cell cycle are largely dependent upon its binding with p53. Almost all 
γH2AX-positive cells were also positive for EdU in wildtype (95.3%), Cul9Δp53/Δp53 
(91.1%), Cul9-/- (90.4%) and p53-/- (97.6%) MEFs, indicating that nearly all spontaneous 
DNA damage occurred during DNA replication in wildtype MEFs and was substantially 
exacerbated by the loss of p53 or Cul9 or the disruption of Cul9-p53 binding. In contrast to 
wildtype MEFs, p53-/-, Cul9-/-, and Cul9 Δp53/Δp53 MEFs all had substantially reduced 
apoptosis in the absence of adding a DNA-damaging agent exogenously or post- etoposide 
treatment, as determined by flow cytometric TUNEL analysis (Figure 3b and Supplementary 
Figures S3a and S3b). Notably, the extent of the suppression of apoptosis was very similar 
between the three mutant MEF lines. Taken together, these results support the notion that 
Cul9 plays a significant role in controlling the function of p53, which in turn regulates the 
cell cycle checkpoint, apoptosis and maintained genome integrity.
Disruption of Cul9-p53 binding increases the rate of MEF cell proliferation and causes MEF 
spontaneous immortalization
Cul9Δp53/Δp53 MEFs were morphologically normal, but appeared to be proliferating at a 
faster rate as shown by higher cell density (Figure 4a). Indeed, when compared to wildtype 
MEF, heterozygous Cul9Δp53/+ MEFs proliferated at a higher rate and the homozygous 
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Cul9Δp53/Δp53 MEFs proliferated even faster (Figure 4b). Surprisingly, when assayed on a 
3T9 proliferation and immortalization protocol14, three independently derived Cul9Δp53/Δp53 
MEF lines underwent spontaneous immortalization, as did Cul9-/- MEFs. In contrast, wild-
type MEFs ceased proliferating around passage 10 (Figure 4c). p53 and Arf, an inhibitor of 
MDM2 and an activator of p53, play the major role in maintaining MEF cellular senescence. 
Wildtype MEFs can escape senescence at a very low frequency, and MEF variants that rarely 
immortalize spontaneously usually sustain a mutation in either p5315 or Arf16, an inhibitor 
of MDM2 and an activator of p53. Deletion of either p53 or Arf or both p53 and Cul9 gene, 
as expected, resulted in MEFs spontaneous immortalization (Figure 4c). Notably, in 
immortalized Cul9Δp53Δp53 or Cul9-/- MEFs spontaneously, both p53 and Arf were retained 
and expressed at levels similar to wildtype MEFs (Figure 4d). This result indicates that 
deletion of Cul9 or disruption of Cul9-p53 binding releases the selection pressure to lose 
either p53 or Arf during cellular immortalization. We noted that both Cul9Δp53/Δp53 and 
Cul9-/- MEFs proliferated at a slower rate compared with either p53-/- and Arf-/- MEFs and 
that p53-/-;Cul9-/- DKO MEFs proliferated at a rate that is indistinguishable from that seen in 
p53-/- MEF (Figure 4c). This result supports the notion that the function of Cul9 in 
regulating cell proliferation is primarily mediated by p53 and also suggests that p53 has 
additional, Cul9-independent activity in regulating cell proliferation.
Discussion
Many p53 modifying enzymes have been extensively characterized 17, and the most widely 
studied p53 modifying enzymes are MDM2 and MDMX E3 ubiquitin ligases. Deletion of 
either Mdm2 or Mdmx/Mdm4 results in mouse embryonic lethality which can be rescued by 
the co-deletion of p5318-20, and p53 has been established as the main functional target of 
both genes during early development. The roles of p53 as the downstream effector of other 
p53 modifying enzymes are yet to be genetically determined, however. The main finding of 
this report is that the function of CUL9 in maintaining genomic integrity is primarily, if not 
entirely mediated by p53. This is based on the quantitative measurement of three functions
—G1-to-S transition, apoptosis and DNA damage—known to be mediated by p53, and it is 
derived from genetic studies from tumor-derived human cells, as well as primary MEFs. 
Notably, these alterations in Cul9 null and Cul9Δp53 MEFs are comparable to those seen in 
p53 null MEFs, suggesting, conversely, that CUL9 plays a significant role in signaling DNA 
damage and G1 checkpoint to p53. Nearly a dozen ubiquitin ligases have been implicated in 
the regulation of p53, all promoting p53 degradation and thereby negatively regulating the 
function of p5321. CUL9 is thus far the only ubiquitin ligase that has been genetically linked 
to p53 activation. The detailed mechanism by which CUL9 activates p53 is currently 
unknown. Although both deletion of CUL9 and disruption of Cul9-p53 binding consistently 
reduced the basal and induced p21 protein level after exposing cells to exogenous DNA-
damaging agent in U2OS and MEF cells, the steady state level of p53 protein was 
appreciably reduced in Cul9 null and Cul9Δp53 MEFs, but not in U2OS cells depleted or 
deleted for CUL9. It is not clear at present whether this disparity reflects a difference 
between human and mouse, or between tumor-derived and primary cells. Lack of significant 
change in p53 protein level in U2OS cells after losing CUL9 function suggests that CUL9 
could activate p53 through a mechanism that is not dependent upon stabilizing p53 protein. 
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It will be important for future studies to determine biochemically how the ubiquitin ligase 
function and cytoplasmic localization of CUL9 lead to p53 activation.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Loss of CUL9 function impairs cellular response to DNA damage in human cells
(a, b). U2OS cells were transfected with indicated siRNAs for 72 hours, either untreated (a) 
or treated with etoposide (2 μM) for indicated length of time presence (b). U2OS cells were 
cultured in McCoy's 5A with 10% FCS and incubated at 37°C, 5% CO2. All siRNA oligos 
were purchased commercially from Invitrogen. siRNA, Stealth RNAi™ siRNA Negative 
Controls LO GC (12935-200) was used as negative control. The siRNA oligo sequences for 
CUL9 are: siCUL9-1: GCUGAGAGACACGUUGUUUAG; siCUL9-2: 
GCUGAAUAAAGGUCUCUUUCU siCUL9-3:UACUGAGGGUGCUCUUCUG. U2OS 
cells cultured on a 6-well plate at 30–40% confluency were transfected with Oligofectamine 
per the manufacturer's protocol (Invitrogen) and analyzed 48-72h after transfection. Cell 
extracts were subjected to immunoblot with indicated antibodies. Data in (b) are presented 
as means ± SD of three independents. (c) Parental CUL9+ and CUL9 deleted U2OS cells 
were treated with 2 μM etoposide for indicated lengths of time. The expressions of proteins 
were determined by immunoblot analysis. (d, e) Parental (p53+, CUL9+), CUL9-KO, p53-
KO and p53-CUL9 DKO U2OS cells were stained with γH2AX antibody antibody (1:500) 
(9718S; Cell Signaling Technology), and DAPI. A representative view is shown on the left. 
Quantifications are shown on the right. 308 CUL9+ and 285 CUL9-KO cells were 
examined, respectively for (d), and 198 parental (p53+, CUL9+), 211 CUL9-KO, 253 p53-
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KO and 209 p53-CUL9 DKO cells were examined for (e). Cells grown in MatTek glass 
bottom dishes were fixed for 10 min in PBS containing 4% paraformaldehyde, washed twice 
with PBS, permeabilized in 0.05% Triton-X at 4 degrees for five minutes, washed once and 
blocked in 2% BSA for 30 min. Cells were incubated with primary antibody in PBS/BSA 
for >2 hr, washed and stained with appropriate fluorescent-conjugated antibody (Jackson 
ImmunoResearch Laboratories) for 90 min. Cells were examined with an Olympus inverted 
microscope with fluorescence illumination source or FV1000 confocal system. The γ-
H2AX foci were analyzed using ImageJ (by NIH Image). The photographs shown are 
representative for each experiment. (f) Cells were harvested at 24 h after drug treatment and 
stained with propidium iodide, followed by flow cytometry analysis. Each panel represents 
the analysis of 20,000 events (cells). Data are presented as means ± SD of three independent 
tests. (g) CUL9+ and CUL9KO U2OS cell were treated with either solvent DMSO or 
etoposide, followed by flow cytometry. Data are presented as means ± SD of three 
independent tests. For cell cycle analysis, after trypsinization and PBS wash, cells were fixed 
by cold ethanol for at least 3 hours. Total DNA was stained by PI (P4170; Sigma).
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Figure 2. Disruption of Cul9-p53 binding impairs cellular response to DNA damage
(a) Disruption of Cul9-p53 binding by the Q418A mutation is verified by IP-western 
analysis. (b) Wild-type and Cul9Δp53/Δp53 MEFs were exposed to etoposide for indicated 
length of time, followed by western blotting. MEFs were maintained in DMEM with 10% 
FCS; all cells were incubated at 37°C, 5% CO2. (c, d) Wild-type, Cul9Δp53/Δp53 and p53-/- 
MEFs were stained with γ-H2AX antibody and DAPI. A representative view is shown on 
the left. Quantification of γ-H2AX-positive cells were scored from 200 WT and 164 
Cul9Δp53/Δp53 MEF cells for (d), and 204 WT and 197 p53-/- MEF cell for (d). (e) Wild-type, 
Cul9-/-, p53-/- and Cul9-/-; p53-/- DKO MEFs were stained with γ-H2AX antibody and 
DAPI. A representative view is shown on the left. Quantification of γ-H2AX-positive cells 
were scored from 169 WT, 196 Cul9-/-, 264 p53-/- and 287 Cul9-/-;p53-/- DKO MEF cells.
Li and Xiong Page 11





















Figure 3. Disruption of Cul9-p53 binding accumulates DNA damage during S-phase and reduces 
apoptosis
(a) MEFs of indicated genotype were pulsed with EdU for 30 min, fixed and stained with 
DAPI and antibody recognizing γ-H2AX and EdU. A representative view is shown on the 
left. Quantification of the percentage of EdU-positive, γ-H2AX-positive, and EdU, γ-H2AX 
double positive cells were scored microscopically from 214 Cul9Δp53/Δp53, 257 Cul9-/- and 
271 p53-/-MEF cells. For simultaneous detecting DNA replication and damage, cells were 
seeded, grown overnight and then were pulsed with EdU for 30 min. Cells were then fixed in 
4% paraformaldehyde in phosphate buffered saline (pH 7.4; PBS). The EdU positive cells 
were detected using the fluorescent azide probe (Lumiprobe), followed by 
immunofluorescence labelling 13. Cells were blocked and permeabilized with 2% BSA in 
PBS for 1 hour and then incubated in γ-H2AX primary antibody (Cell Signaling, 1:500) for 
2-3 hours. Cells were then incubated with secondary antibody for 1 hour at room 
temperature, after 3 times wash, the cells were stained with DAPI to visualize the nuclei. 
Cells were examined with an Olympus inverted microscope with fluorescence illumination 
source or FV1000 confocal system. For each EdU experiment, multiple randomly selected 
fields were imaged and the numbers EdU positive cells and the γ-H2AX foci were analyzed 
using ImageJ (by NIH Image). (b) Untreated and etoposide-treated MEFs of different 
genotypes were stained with Annexin V and PI, followed by flow cytometric analysis. 
Quantifications of total apoptosis are shown. For apoptosis or cell death analysis, cells were 
harvested by trypsinization, stained with Annexin V–7AAD and then analyzed by FACS. 
FACS analysis was performed using the CYAN ADP Analyzer (Dako, Fort Collins, 
Colorado). Data analysis was performed using Summit v4.3 software (Dako).
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Figure 4. Disruption of Cul9-p53 binding increases the rate of MEF cell proliferation and causes 
MEF spontaneous immortalization
(a) Morphological comparison of wildtype and Cul9QA/QA MEFs at early and late passages. 
(b) 5×105 early passage (P3) MEFs of different genotypes were seeded and cell numbers 
counted over a period of 9 days. (c) MEFs with indicated genotypes were passaged in vitro 
on defined 3T9 protocol. Growth curves of MEFs at early passage (< passage 4) were 
determined by plating 2×103 cells in 35 mm diameter dishes; duplicate cultures were 
harvested every day thereafter and cells were counted. Serial cultures were done according 
to the 3T9 protocol. Briefly, 1×106 cells were plated on a 100-mm dish in DMEM/10% FBS, 
and cell numbers were counted after three days of culture. 1×106 cells were plated again and 
the procedure was repeated for 20 passages. For cell cycle analysis, early passage MEFs (< 
passage 4) from individual embryos were plated in 100-mm plates and incubated in DMEM 
plus 10% FBS for 24 h. (d) Total cell extracts were prepared from wildtype and mutant MEF 
at early passage or after immortalization. The levels of individual proteins were determined 
by western blotting with indicated antibodies.
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